Personalized Bacteriophage Therapy to Treat Pandrug-resistant Spinal Pseudomonas Aeruginosa Infection

Overview

Journal Nat Commun

Specialty Biology

Date 2022 Jul 22

PMID 35869081

Authors

T Ferry

C Kolenda

F Laurent

G Leboucher

M Merabischvilli

S Djebara

C-A Gustave

T Perpoint

C Barrey

J-P Pirnay

G Resch

Affiliations

Soon will be listed here.

Abstract

Bone and joint infections (BJI) are one of the most difficult-to-treat bacterial infection, especially in the era of antimicrobial resistance. Lytic bacteriophages (phages for short) are natural viruses that can selectively target and kill bacteria. They are considered to have a high therapeutic potential for the treatment of severe bacterial infections and especially BJI, as they also target biofilms. Here we report on the management of a patient with a pandrug-resistant Pseudomonas aeruginosa spinal abscess who was treated with surgery and a personalized combination of phage therapy that was added to antibiotics. As the infecting P. aeruginosa strain was resistant to the phages developed by private companies that were contacted, we set up a unique European academic collaboration to find, produce and administer a personalized phage cocktail to the patient in due time. After two surgeries, despite bacterial persistence with expression of small colony variants, the patient healed with local and intravenous injections of purified phages as adjuvant therapy.

Citing Articles

Evaluating human exposure to antibiotic resistance genes.

Zhou Z, Chen H Biosaf Health. 2025; 6(2):98-100.

PMID: 40078948 PMC: 11895025. DOI: 10.1016/j.bsheal.2024.02.005.

In Vitro Activity of Bacteriophages Against Ocular Methicillin-resistant S. aureus Isolates Collected in the US.

Andre C, Medina M, Kolenda C, Blaziere L, Helluin E, Resch G Ophthalmol Ther. 2025; .

PMID: 40072828 DOI: 10.1007/s40123-025-01113-2.

Emerging antimicrobial therapies for Gram-negative infections in human clinical use.

Hickson S, Ledger E, Wells T NPJ Antimicrob Resist. 2025; 3(1):16.

PMID: 40016340 PMC: 11868545. DOI: 10.1038/s44259-025-00087-2.

Enhancing phage therapy by coating single bacteriophage-infected bacteria with polymer to preserve phage vitality.

Lin S, Xie G, He J, Meng L, Pang Y, Liu J Nat Biomed Eng. 2025; .

PMID: 40000896 DOI: 10.1038/s41551-025-01354-3.

Enhanced suppression of by a three-phage cocktail: genomic insights and kinetic profiling.

Monsibais A, Tea O, Ghatbale P, Dunham S, Zund M, Phan J Antimicrob Agents Chemother. 2025; 69(3):e0116224.

PMID: 39840957 PMC: 11881566. DOI: 10.1128/aac.01162-24.

References

Djebara S, Maussen C, De Vos D, Merabishvili M, Damanet B, Pang K . Processing Phage Therapy Requests in a Brussels Military Hospital: Lessons Identified. Viruses. 2019; 11(3). PMC: 6466067. DOI: 10.3390/v11030265. View

Petrovic Fabijan A, Lin R, Ho J, Maddocks S, Ben Zakour N, Iredell J . Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nat Microbiol. 2020; 5(3):465-472. DOI: 10.1038/s41564-019-0634-z. View

Kolenda C, Josse J, Medina M, Fevre C, Lustig S, Ferry T . Evaluation of the Activity of a Combination of Three Bacteriophages Alone or in Association with Antibiotics on Staphylococcus aureus Embedded in Biofilm or Internalized in Osteoblasts. Antimicrob Agents Chemother. 2019; 64(3). PMC: 7038305. DOI: 10.1128/AAC.02231-19. View

Pires D, Costa A, Pinto G, Meneses L, Azeredo J . Current challenges and future opportunities of phage therapy. FEMS Microbiol Rev. 2020; 44(6):684-700. DOI: 10.1093/femsre/fuaa017. View

Taheri Y, Jokovic N, Vitorovic J, Grundmann O, Maroyi A, Calina D . The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol. Front Pharmacol. 2021; 11:578823. PMC: 7898678. DOI: 10.3389/fphar.2020.578823. View

Onsea J, Soentjens P, Djebara S, Merabishvili M, Depypere M, Spriet I . Bacteriophage Application for Difficult-to-treat Musculoskeletal Infections: Development of a Standardized Multidisciplinary Treatment Protocol. Viruses. 2019; 11(10). PMC: 6832313. DOI: 10.3390/v11100891. View

Biagi M, Vialichka A, Jurkovic M, Wu T, Shajee A, Lee M . Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2020; 64(9). PMC: 7449157. DOI: 10.1128/AAC.00559-20. View

Pirnay J, Verbeken G, Ceyssens P, Huys I, De Vos D, Ameloot C . The Magistral Phage. Viruses. 2018; 10(2). PMC: 5850371. DOI: 10.3390/v10020064. View

Jault P, Leclerc T, Jennes S, Pirnay J, Que Y, Resch G . Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2018; 19(1):35-45. DOI: 10.1016/S1473-3099(18)30482-1. View

10.

Nir-Paz R, Gelman D, Khouri A, Sisson B, Fackler J, Alkalay-Oren S . Successful Treatment of Antibiotic-resistant, Poly-microbial Bone Infection With Bacteriophages and Antibiotics Combination. Clin Infect Dis. 2019; 69(11):2015-2018. DOI: 10.1093/cid/ciz222. View

11.

Ferry T, Kolenda C, Batailler C, Gaillard R, Gustave C, Lustig S . Case Report: Arthroscopic "Debridement Antibiotics and Implant Retention" With Local Injection of Personalized Phage Therapy to Salvage a Relapsing Prosthetic Knee Infection. Front Med (Lausanne). 2021; 8:569159. PMC: 8132876. DOI: 10.3389/fmed.2021.569159. View

12.

Geneviere J, McCallin S, Huttner A, Pham T, Suva D . A systematic review of phage therapy applied to bone and joint infections: an analysis of success rates, treatment modalities and safety. EFORT Open Rev. 2022; 6(12):1148-1156. PMC: 8722473. DOI: 10.1302/2058-5241.6.210073. View

13.

Chegini Z, Khoshbayan A, Moghadam M, Farahani I, Jazireian P, Shariati A . Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review. Ann Clin Microbiol Antimicrob. 2020; 19(1):45. PMC: 7528332. DOI: 10.1186/s12941-020-00389-5. View

14.

Cerioli M, Batailler C, Conrad A, Roux S, Perpoint T, Becker A . Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center in France. Front Med (Lausanne). 2020; 7:513242. PMC: 7649271. DOI: 10.3389/fmed.2020.513242. View

15.

Pirnay J, Ferry T, Resch G . Recent progress toward the implementation of phage therapy in Western medicine. FEMS Microbiol Rev. 2021; 46(1). DOI: 10.1093/femsre/fuab040. View

16.

Ferry T, Kolenda C, Briot T, Souche A, Lustig S, Josse J . Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection. Viruses. 2021; 13(12). PMC: 8708067. DOI: 10.3390/v13122414. View

17.

Koder K, Hardt S, Gellert M, Haupenthal J, Renz N, Putzier M . Outcome of spinal implant-associated infections treated with or without biofilm-active antibiotics: results from a 10-year cohort study. Infection. 2020; 48(4):559-568. PMC: 7395063. DOI: 10.1007/s15010-020-01435-2. View